brolucizumab
Beovu (Anti-VEGF)
Plain-language definition
An anti-VEGF antibody fragment for wet AMD, designed for longer treatment intervals. Brand name: Beovu. Carries a small risk of intraocular inflammation.
Where this term comes up
“Brolucizumab (Beovu)”
Treatment · Intravitreal Injection
“Brolucizumab (Beovu)”
Condition · Wet Age-Related Macular Degeneration (Wet AMD)
“Brolucizumab (Beovu) - every 8-12 weeks after loading”
Condition · Macular Degeneration (AMD)
- Category
- Medication
- Also written as
- No alternate forms listed.
Medication terms describe drugs or drug classes that may be used in eye care, neurology, inflammation, infection, or pain treatment.
Related glossary terms
- aflibercept
Eylea (Anti-VEGF)
- anti-VEGF
Anti-Vascular Endothelial Growth Factor
- bevacizumab
Avastin (Off-Label Anti-VEGF)
- faricimab
Vabysmo (Bispecific Antibody)
- ranibizumab
Lucentis (Anti-VEGF)
- AMD
Age-Related Macular Degeneration
A note on medical context
A glossary definition can explain a word, but it cannot tell you whether a symptom or test result is serious. If this term came from an article, use the full article and your clinician's guidance for context.